Celiac disease and hypothyroidism
Abstract
Background Celiac disease is more common in patients with hypothyroidism. Malabsorption of levothyroxine has not been studied in this population. We sought to determine if levothyroxine dosing was influenced by the presence and treatment of celiac disease.Methods This retrospective study was conducted at an academic medical center. Cases had hypothyroidism and celiac disease. Controls had hypothyroidism alone and were selected randomly through the endocrinology clinic records. Celiac disease was defined as representative pathology with positive serology. Age, sex, height, weight, body mass index, creatinine, and medical comorbidity were assessed for cases and controls. The levothyroxine dose and weight-based levothyroxine dose necessary to maintain a euthyroid state was evaluated for controls, and before and after celiac disease therapy for cases.Results Celiac disease was identified in 152 patients, and 22 patients had concomitant hypothyroidism (14.5%). Seven cases met inclusion criteria. Overall, 200 control patients were identified. The mean celiac disease pretreatment levothyroxine dose and weight-based levothyroxine dose needed to maintain a euthyroid state were higher in cases than in controls (154 μg vs 106 μg, P=.007, and 2.6 μg/kg vs 1.3 μg/kg, P <.001). Doses decreased significantly after treatment of celiac disease (154 μg vs 111 μg, P=.03; and 2.64 μg/kg vs 1.89 μg/kg, P=.04). All cases required at least 125 μg of levothyroxine initially to maintain a euthyroid state.Conclusions Levothyroxine malabsorption likely occurs with hypothyroidism and untreated celiac disease. Absorption may improve after celiac disease treatment. Screening for celiac disease in patients with hypothyroidism requiring elevated levothyroxine doses warrants further investigation.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A lactose-free formulation or gluten-free diet can rid patients with lactose intolerance or celiac disease of impaired absorption.
“A lactose-free formulation or gluten-free diet can rid patients with lactose intolerance or celiac disease of impaired absorption, respectively (14, 64).”
From Levothyroxine: conventional and novel drug delivery formulations. (2023) · cites this paper as [64]
Many patients with malabsorption can have a serum TSH level in the target range with an increased dose of LT4.
“Many patients with malabsorption can have a serum TSH level in the target range with an increased dose of LT4 (64, 70).”
From Levothyroxine: conventional and novel drug delivery formulations. (2023) · cites this paper as [64]
To reach an equivalent TSH level, LT4 dose must be higher if the patient's intestinal tract is affected by ulcerative colitis, coeliac disease, lactose intolerance, gastritis (especially H. pylori-related and autoimmune gastritis), and Giardia lamblia infection.
“To reach an equivalent TSH level, the LT4 dose must be higher if the patient’s intestinal tract is affected by ulcerative colitis [ 49 ], coeliac disease [ 50 ], lactose intolerance [ 51 ], and gastritis (especially Helicobacter pylori –related gastritis and autoimmune gastritis) [ 43 , 52 – 54 ], and infections with Giardia lamblia (giardiasis) [ 55 ].”
From Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults (2022) · cites this paper as [50]
The citation lists haven’t been fetched yet
References 23 · Cited by 54
- Authors
- Collins, D., Wilcox, R., Nathan, M., & Zubarik, R.
- Affiliations
- University of Vermont (US)
- Corresponding author
- Zubarik, Richard
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 125
- Issue
- 3
- Pages
- 278-282
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2024894443
- Cited by
- 54
- References
- 23
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2022: 7 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 6 · 2017: 3 · 2016: 3 · 2015: 7 · 2014: 3 · 2013: 7 · 2012: 3
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Celiac Disease Research and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- celiac disease, hypothyroidism, levothyroxine, celiac disease treatment
- MeSH terms
- Celiac Disease, Female, Humans, Hypothyroidism, Male, Middle Aged, Retrospective Studies, Thyroxine, Comorbidity, Chi-Square Distribution, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review